All Digests

July 8, 2026 5 stories

Axios/Chainalysis: Chinese Fentanyl Makers Pivot to Peptides ($27M Q1 Crypto Payments), Kalohexis Files Confidential IPO on MC3R/MC4R Melanocortin Obesity Program, FDA 23 Novel Drug Approvals Through June Match Best First-Half Since 2023 Despite Staff Cuts, Vera Therapeutics Trutakna (Atacicept) IgA Nephropathy Accelerated Approval, PCAC Written-Comment Docket Closes Tomorrow for Member Review

Axios: Chinese fentanyl makers pivot to peptides; Kalohexis IPO on MC3R/MC4R obesity; FDA 23 novel approvals; Vera Trutakna approved; PCAC comment cutoff Jul 9.

Read digest →

July 7, 2026 6 stories

Vivani and Novo Nordisk Partner on a Semaglutide Implant, Kailera's Oral GLP-1 Clears Phase 3 in China, a JAMA Secret-Shopper Study on Online GLP-1 Prescribing, Ascletis Files Amylin-Peptide INDs

Vivani and Novo partner on a semaglutide implant, Kailera's oral GLP-1 clears Phase 3 in China, and a JAMA study finds online GLP-1 prescribing fast and loose.

Read digest →

July 6, 2026 3 stories

Jerome Adams Pitches a Regulated 503A Middle Path for Peptides, Medicare GLP-1 Bridge Denials Trace to a Billing Code, Lantheus Draws an Edotreotide CRL

Jerome Adams pitches a regulated 503A middle path for peptides, Medicare GLP-1 Bridge denials trace to a billing code, and Lantheus draws an edotreotide CRL.

Read digest →

July 3, 2026 4 stories

KFF Full Analysis Projects Medicare GLP-1 Bridge Cost at $1.3-10 Billion Across the 18-Month Demonstration, FDA Accepts Sandoz Generic Tirzepatide ANDAs to Open First-Generic Race, UC Davis Paul Knoepfler Says RFK Jr. 'Stacked the Committee,' BPC-157 Pipeline Retrospective Ahead of July 23 PCAC Vote

KFF projects Bridge cost $1.3-10B; Sandoz generic tirzepatide ANDAs accepted; Knoepfler 'stacked' quote; BPC-157 pipeline retrospective ahead of PCAC.

Read digest →

July 2, 2026 5 stories

Novo Nordisk's Jamey Millar Statement on Wegovy Access Through Medicare Bridge, Pep Club Full-Stack Peptide + Biomarker Telehealth Launch, US News AP Wire on FDA Scientists Warning Against Expanded Peptide Access, PolitiFact Retatrutide Compassionate-Use Primer, Bridge Day 2 Operations

Novo Millar statement on Wegovy Bridge access; Pep Club telehealth launch; US News/AP FDA scientists warning; PolitiFact retatrutide primer; Bridge Day 2.

Read digest →

July 1, 2026 5 stories

Medicare GLP-1 Bridge Launches Today at $50/Month Copay, KFF Estimates 3.8 Million Eligible Beneficiaries, Becker's Payer Flags Four Lingering Questions, Public Citizen and BioCentury Critic Chorus Against RFK Jr. Peptide Deregulation Ahead of July 23-24 PCAC

Medicare GLP-1 Bridge launches at $50/month; 3.8M eligible per KFF; 4 questions linger per Becker's; Public Citizen and BioCentury oppose peptide deregulation.

Read digest →

June 30, 2026 6 stories

FDA Career Scientists Briefing Document Says No Peptide Has Sufficient Evidence for 503A Bulks List, STAT: Eight New PCAC Panelists Carry Peptide Industry Ties, PCAC Oral Testimony Closes Today, Medicare GLP-1 Bridge Launches Tomorrow

FDA scientists flag insufficient evidence on 7 peptides; STAT scoops PCAC panelist conflicts; oral testimony closes today; Medicare Bridge launches July 1.

Read digest →

June 29, 2026 6 stories

FDA 503B GLP-1 Exclusion Comment Deadline Closes Today, Medicare GLP-1 Bridge Mainstream-Media Coverage Wave, PCAC Oral Testimony Closes Tuesday, Zymeworks-Theravance $929M Acquisition, Pharmacy Times Lambert Pharmacist Guidance, Leerink Cherny Calls PCAC 'Modest Binary Event' for HIMS

FDA 503B GLP-1 comments close today; Medicare Bridge media wave; PCAC testimony Tuesday; Zymeworks-Theravance $929M; pharmacist guidance; HIMS analyst notes.

Read digest →

June 28, 2026 3 stories

Sacred Eye Beauty Launches 30-Day Ritual with GHK-Cu Skin Magic Tablets, FDA 503B GLP-1 Exclusion Comment Deadline Closes Monday June 29, Regulatory Week Ahead: PCAC Testimony Cutoff and Medicare GLP-1 Bridge Launch

Sacred Eye Beauty 30-Day Ritual launches with GHK-Cu/PQQ/Methylene Blue; FDA 503B GLP-1 comment deadline June 29; regulatory week ahead Mon-Wed.

Read digest →

June 27, 2026 3 stories

STAT BIO 2026 Closing Wrap on AI Dominance and China Anxiety, UVA's Dr. Catherine Varney Will Not Prescribe BPC-157 or TB-500, Medscape: Unapproved Retatrutide Poison-Center Exposures Up 265% as 50+ Clinics Openly Advertise

STAT BIO 2026 wrap on AI + China; UVA Dr. Varney warns BPC-157/TB-500 evidence is animal-only; Medscape: retatrutide poison exposures up 265%.

Read digest →

June 26, 2026 7 stories

Sangamo Files Chapter 11 with Lilly $50M Stalking-Horse Bid, 18 Bioethics Experts Call Retatrutide Compassionate Use Unusual, ONVAX-01 Peptide Nanovaccine in Pancreatic Cancer, HIMS June 25% Rally on Novo 'Voluminous Partner' Label, Medicare GLP-1 Bridge 5 Days Out, Brain Peptides Alzheimer's Review

Sangamo Chapter 11 + Lilly $50M; 18 bioethics experts on retatrutide; ONVAX-01; HIMS rally; Medicare GLP-1 Bridge July 1; brain peptides Alzheimer's review.

Read digest →

June 25, 2026 4 stories

Senator Hassan Letter to RFK Jr Asks if Trump Is Retatrutide Patient, Lilly's First Public Statement, Rep. Lieu Suggests Terminal Illness, BIO 2026 Closes in San Diego

Hassan letter to RFK Jr on retatrutide compassionate use; Lilly's first statement; Lieu terminal-illness press conference; BIO 2026 wraps June 25.

Read digest →

June 24, 2026 5 stories

Lilly Halves €2.3B Alzey Germany Plant on Dynamic Manufacturer Rebate, White House Calls STAT Reporter Names Over Retatrutide Story, PCAC Oral Testimony Deadline June 30, ML-Discovered Anti-Pseudomonas AMPs

Lilly halves Alzey plant on German pricing reform; White House escalates retatrutide pushback; PCAC oral testimony deadline June 30; anti-Pseudomonas AMPs.

Read digest →

June 23, 2026 4 stories

STAT Breaks FDA-Lilly Retatrutide Compassionate-Use for Mystery 79-Year-Old, Elicio AMPLIFY-7P KRAS Vaccine Misses Phase 2 Primary, Hims & Hers Stock Above $30 on PCAC Catalyst, Medicare GLP-1 Bridge Launches July 1

STAT: FDA-Lilly retatrutide compassionate use for mystery 79-year-old; Elicio AMPLIFY-7P miss; Hims stock above $30 on PCAC; Medicare GLP-1 Bridge July 1.

Read digest →

June 22, 2026 6 stories

BIO 2026 Opens San Diego: BioArctic-Lilly $800M BrainTransporter Pact, Novo Wegovy MASH Approved in Japan, TGA Australia Peptide Compliance Crackdown, USTR Germany Section 301, AGA POWER Framework Revision, Indena-Chemi PDC Partnership

BIO 2026 Day 1 brings BioArctic-Lilly $800M BrainTransporter pact; Wegovy MASH approved in Japan; TGA peptide crackdown; USTR Germany 301; AGA POWER revision.

Read digest →

June 21, 2026 5 stories

CKYN GHK-Cu Skincare Launch June 20, JN GLP-1 Malnutrition Review June 20, Pfizer CFO Transition, Biogen Closes $5.6B Apellis Acquisition Adding Cyclic Peptide Pegcetacoplan, BIO 2026 Opens San Diego June 22

CKYN Complete GHK-Cu Protocol launch, JN GLP-1 malnutrition review, Pfizer CFO transition, Biogen completes $5.6B Apellis acquisition, BIO 2026 opens June 22.

Read digest →

June 20, 2026 7 stories

HLB RGN-259 SEER-3 Phase 3 Miss, NervGen NVG-291 RESTORE Phase 3 Mid-2026, EndoCyclic ENDO-205 IND Cleared for Endometriosis, Bachem CCO Transition, CROI 2026 GLP-1 + HIV, PharmTech Peptide Manufacturing Feature

HLB RGN-259 SEER-3 miss, NervGen NVG-291 RESTORE Phase 3 mid-2026, EndoCyclic ENDO-205 IND endometriosis, Bachem CCO, CROI GLP-1 in HIV.

Read digest →

June 19, 2026 10 stories

Marea MAR002 First-in-Class Anti-GHR Antibody Phase 1 at ENDO 2026, EMA Synthetic Peptide Guideline Effective, Pep2Tango PTT-A Tetra-Agonist Beats Tirzepatide, France Wegovy/Mounjaro Reimbursement Live, BU Sontha 60K-Patient GLP-1 Discontinuation Study, Italgel + GELITA Collagen Peptide Launches

Marea MAR002 anti-GHR Phase 1 at ENDO 2026, EMA synthetic peptide guideline effective, Pep2Tango PTT-A 19%, France Wegovy reimbursement, Sontha 60K GLP-1 data.

Read digest →